{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:12:50Z","timestamp":1767985970358,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"DOI":"10.7759\/cureus.101163","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:11:18Z","timestamp":1767967878000},"source":"Crossref","is-referenced-by-count":0,"title":["cN1A Antibody-Positive Inclusion Body Myositis Following Seminoma Manifesting With Slowly Progressive Paraparesis: A Case Report"],"prefix":"10.7759","author":[{"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137358","article-title":"Inclusion body myositis and neoplasia: a narrative review","volume":"23","author":"Damian L","year":"2022","unstructured":"Damian L, Login CC, Solomon C, et al.. Inclusion body myositis and neoplasia: a narrative review. Int J Mol Sci. 2022, 23:7358. 10.3390\/ijms23137358","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1020113","article-title":"Inclusion body myositis: update on the diagnostic and therapeutic landscape","volume":"13","author":"Naddaf E","year":"2022","unstructured":"Naddaf E. Inclusion body myositis: update on the diagnostic and therapeutic landscape. Front Neurol. 2022, 13:1020113. 10.3389\/fneur.2022.1020113","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/r625rm","article-title":"Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis","volume":"40","author":"Salam S","year":"2022","unstructured":"Salam S, Dimachkie MM, Hanna MG, Machado PM. Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis. Clin Exp Rheumatol. 2022, 40:384-93. 10.55563\/clinexprheumatol\/r625rm","journal-title":"Clin Exp Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000278","article-title":"Positive cytosolic 5-nucleotidase 1A antibodies in motor neuron disease","volume":"22","author":"Assadi RK","year":"2020","unstructured":"Assadi RK, Manousakis G. Positive cytosolic 5-nucleotidase 1A antibodies in motor neuron disease. J Clin Neuromuscul Dis. 2020, 22:50-2. 10.1097\/CND.0000000000000278","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab423","article-title":"Significance of Sj\u00f6gren's syndrome and anti-cN1A antibody in myositis patients","volume":"61","author":"Levy D","year":"2022","unstructured":"Levy D, Nespola B, Giannini M, et al.. Significance of Sj\u00f6gren's syndrome and anti-cN1A antibody in myositis patients. Rheumatology (Oxford). 2022, 61:756-63. 10.1093\/rheumatology\/keab423","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03521-4","article-title":"Coexistence of CN1A autoantibodies in GAD65 encephalitis exacerbates neurodegeneration : novel autoantibodies in GAD65 encephalitis","volume":"22","author":"Breuer A","year":"2025","unstructured":"Breuer A, Kamalizade D, Baumgartner T, et al.. Coexistence of CN1A autoantibodies in GAD65 encephalitis exacerbates neurodegeneration : novel autoantibodies in GAD65 encephalitis. J Neuroinflammation. 2025, 22:194. 10.1186\/s12974-025-03521-4","journal-title":"J Neuroinflammation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092944","article-title":"Prevalence of novel myositis autoantibodies in a large cohort of patients with interstitial lung disease","volume":"9","author":"Moll SA","year":"2020","unstructured":"Moll SA, Platenburg MG, Platteel AC, et al.. Prevalence of novel myositis autoantibodies in a large cohort of patients with interstitial lung disease. J Clin Med. 2020, 9:2944. 10.3390\/jcm9092944","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.06.005","article-title":"Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center","volume":"28","author":"Felice KJ","year":"2018","unstructured":"Felice KJ, Whitaker CH, Wu Q, Larose DT, Shen G, Metzger AL, Barton RW. Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center. Neuromuscul Disord. 2018, 28:660-4. 10.1016\/j.nmd.2018.06.005","journal-title":"Neuromuscul Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2021.08.015","article-title":"Total thyroidectomy can be overtreatment in cN1a papillary thyroid carcinoma patients whose tumor is smaller than 1\u00a0cm","volume":"223","author":"Back K","year":"2022","unstructured":"Back K, Lee J, Choe JH, Kim JH, Oh YL, Kim JS. Total thyroidectomy can be overtreatment in cN1a papillary thyroid carcinoma patients whose tumor is smaller than 1\u00a0cm. Am J Surg. 2022, 223:635-40. 10.1016\/j.amjsurg.2021.08.015","journal-title":"Am J Surg"},{"key":"ref10","article-title":"Inclusion Body Myositis","author":"Panginikkod S","year":"2025","unstructured":"Panginikkod S, Musa R. Inclusion Body Myositis. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26830","article-title":"Inclusion-body myositis and primary Sj\u00f6gren syndrome: mechanisms for shared etiologies","author":"Limaye VS","year":"2020","unstructured":"Limaye VS, Cash K, Smith C, Koszyca B, Patel S, Greenberg SA, Hissaria P. Inclusion-body myositis and primary Sj\u00f6gren syndrome: mechanisms for shared etiologies. Muscle Nerve. 2020. 61:570-4. 10.1002\/mus.26830"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert MK","year":"2016","unstructured":"Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al.. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016, 75:696-701. 10.1136\/annrheumdis-2014-206691","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5'-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd TE","year":"2016","unstructured":"Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al.. Cytosolic 5'-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken). 2016, 68:66-71. 10.1002\/acr.22600","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448578-cn1a-antibody-positive-inclusion-body-myositis-following-seminoma-manifesting-with-slowly-progressive-paraparesis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:11:19Z","timestamp":1767967879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448578-cn1a-antibody-positive-inclusion-body-myositis-following-seminoma-manifesting-with-slowly-progressive-paraparesis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.101163","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}